Advertisement

Perinatal Coagulation and Fibrinolysis

  • John Bonnar
  • Leisha Daly
  • Brian L. Sheppard

Abstract

In normal pregnancy extensive changes take place in the hemostatic system, involving in particular the coagulation and fibrinolytic systems. These physiological changes seem to have two major interrelated functions. First, to maintain the integrity of the expanding maternal and fetal circulations at the interface of the placenta and, secondly, to ensure the rapid and effective control of bleeding from the placental site during and after placental separation.

Keywords

Plasminogen Activator Inhibitor Normal Pregnancy Fibrin Deposition Spiral Artery Fibrin Degradation Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sheppard B, Bonnar J (1974) The ultrastructure of the arterial supply of the human placenta in early and late pregnancy. J Obstet Gynaecol Br Cwlth 81: 497–511CrossRefGoogle Scholar
  2. 2.
    Bonnar J, McNicol GP, Douglas AS (1969) Fibrinolytic enzyme system and pregnancy. Br Med J 3: 387–395PubMedCrossRefGoogle Scholar
  3. 3.
    MacFarlane RG, Biggs R (1946) Observations on fibrinolysis; spontaneous activity associated with surgical operations, trauma and c. Lancet II: 862–864CrossRefGoogle Scholar
  4. 4.
    Biezenski JJ, Moore HC (1958) Fibrinolysis in normal pregnancy. J Clin Pathol 11: 306–310PubMedCrossRefGoogle Scholar
  5. 5.
    Shaper AG, Macintosh DM, Evans CM, Kyope J (1965) Fibrinolysis and plasminogen levels in pregnancy and the puerperium. Lancet II: 706–708CrossRefGoogle Scholar
  6. 6.
    Sheppard BL, Bonnar J (1976) The ultrastructure of the arterial supply of the human placenta in pregnancy complicated by fetal growth retardation. Br J Obstet Gynaecol 83: 948–959PubMedCrossRefGoogle Scholar
  7. 7.
    Sheppard BL, Bonnar J (1978) Fibrinolysis in decidual spiral arteries in late pregnancy. Thromb Haemost 39: 751–758PubMedGoogle Scholar
  8. 8.
    Sheppard BL, Bonnar J (1981) An ultrastructural study of utero-placental spiral arteries in hypertensive and normotensive pregnancy and fetal growth retardation. Br J Obstet Gynaecol 88: 695–705PubMedCrossRefGoogle Scholar
  9. 9.
    Sheppard BL, Boyle C, Gleeson N, Jordan M, Daly L, Bonnar J (1990) Plasminogen activator inhibitors of the placenta and placental bed at delivery in normotensive and hypertensive pregnancy. Placental communications. Biochem Morphol Cell Aspects 199: 151–159Google Scholar
  10. 10.
    Stirling Y, Woolf, L, North WRS, Seghatchian MJ, Meade TW (1984) Haemostasis in normal pregnancy. Thromb Haemost 52: 176–182PubMedGoogle Scholar
  11. 11.
    Kawano T, Morimoto K, Uemura Y (1968) Urokinase inhibitor in human placenta. Nature 217: 253–254PubMedCrossRefGoogle Scholar
  12. 12.
    Astedt B, Pandolphi M, Nilsson IM (1972) Inhibitory effect of placenta on plasminogen activation in human organ culture. Proc Soc Exp Biol Med 139: 1421–1424PubMedGoogle Scholar
  13. 13.
    Astedt B, Hagerstrom I, Lecander I (1986) Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 56: 63–65PubMedGoogle Scholar
  14. 14.
    Kruithof EKO, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F (1987) Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 69: 460–466PubMedGoogle Scholar
  15. 15.
    Lecander I, Astedt B (1986) Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 62: 221–228PubMedCrossRefGoogle Scholar
  16. 16.
    Astedt B, Lecander I, Brondin T, Lundblad A, Low K (1985) Purification of a specific placental plasminogen activator by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 53: 122–125PubMedGoogle Scholar
  17. 17.
    Astedt B, Lecander I, Ny T (1987) Review The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1: 203–208Google Scholar
  18. 18.
    Douglas JT, Shah M, Lowe GDO, Belch JJF, Forbes CD, Prentice CRM (1982) Plasma fibrinopeptide A and beta-thromboglobulin in pre-eclampsia and pregnancy hypertension. Thromb Haemost 47: 54–55PubMedGoogle Scholar
  19. 19.
    Astedt B (1972) On fibrinolysis in pregnancy, labour, puerperium, and during treatment with sex hormones. Acta Obstet Gynecol Scand 51: (Suppl. 8): 1–24CrossRefGoogle Scholar
  20. 20.
    Bonnar J, McNicol GP, Douglas AS (1970) Coagulation and fibrinolytic mechanisms during and after normal childbirth. Br Med J 2: 200–203PubMedCrossRefGoogle Scholar
  21. 21.
    Wiman B, Csemiczky, Marsk L, Robbe H (1984) The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemost 52: 124–126PubMedGoogle Scholar
  22. 22.
    Astedt B, Lecander I, Nilsson IM (1986) Depression of PA activity during pregnancy by the placenta inhibitor fibrinolysis. Proceedings of the eighth international congress on fibrinolysis, p. 185Google Scholar
  23. 23.
    Wright JG, Cooper P, Astedt B, Lecander I, Wilde JT, Preston FE, Greaves M (1988) Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time. Br J Haematol 69: 253–258PubMedCrossRefGoogle Scholar
  24. 24.
    Fletcher AP, Alkjaersig NK, Burstein R (1979) The influence of pregnancy upon blood coagulation and plasma fibrinolytic enzyme function. Am J Obstet Gynecol. 134: 743–751PubMedGoogle Scholar
  25. 25.
    Gaffney PJ, Creighton LJ, Callus M, Thorpe R (1988) Monoclonal antibodies to cross-linked fibrin degradation products (XL-FDP) II. Evaluation in a variety of clinical conditions. Br J Haematol 68: 91–96PubMedCrossRefGoogle Scholar
  26. 26.
    Astedt B, Bladh B, Christensen U, Lecander I (1985) Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates. Scand J Clin Lab Invest 45: 429–435PubMedGoogle Scholar
  27. 27.
    Bonnar J, McNicol GP, Douglas AS (1971) Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia. Br Med J II: 12–16CrossRefGoogle Scholar
  28. 28.
    Howie PW, Prentice CRM, McNicol GP (1971) Coagulation, fibrinolysis and platental function in pre-eclampsia, essential hypertension, and placental insufficiency. J Obstet Gynaecol Br Cwlth 78: 992–1003CrossRefGoogle Scholar
  29. 29.
    Gow L, Campbell DM, Ogston D (1984) The fibrinolytic system in pre-eclampsia. J Clin Pathol 37: 56–58PubMedCrossRefGoogle Scholar
  30. 30.
    Aznar J, Gilabert J, Estelies A, Espana F (1986) Finbrinolytic activity and Protein C in pre-eclampsia. Thromb Haemost 55: 314–317PubMedGoogle Scholar
  31. 31.
    Estelies A, Gilabert J, Aznar J, Scheef RR (1988) Plasminogen activator inhibitors type 1 and type 2 (PAI-1 and PAI-2) in normal pregnancy and in patients with severe pre-eclampsia. Fibrinolysis 2: 162Google Scholar
  32. 32.
    Giles C (1982) Intravascular coagulation in gestational hypertension and pre-eclampsia: the value of haematological screening tests. Clin Lab Haematol 4: 351–358PubMedCrossRefGoogle Scholar
  33. 33.
    Borok Z, Weitz J, Owen J, Auerbach M, Nossel HL (1984) Fibrinogen proteolysis and platelet alpha-granule release in pre-eclampsia/eclampsia. Blood 63: 525–531PubMedGoogle Scholar
  34. 34.
    Daly L, Bonnar J (1989) Fibrinolytic activation and inhibition in normal pregnancy and in pre-eclampsia. To be publishedGoogle Scholar

Copyright information

© Springer Japan 1991

Authors and Affiliations

  • John Bonnar
    • 1
  • Leisha Daly
    • 1
  • Brian L. Sheppard
    • 1
  1. 1.Trinity College Department of Obstetrics and GynaecologySt James’s Hospital and Coombe HospitalDublinIreland

Personalised recommendations